demonstrated suggested inconclusive safety concern ongoing study display ongoing demontrated benefit only
COVID-19 mild to moderate
COVID 19 hospitalizedCOVID-19 mild to moderate
inhaled interferon
IFN alpha
pegylated interferon-α2b Pandit Shashi Bhushan
recombinant super-compound interferon rSIFN-co Li
SNG001 inhaled interferon beta Synairgen SG016

1 studies excluded by filtering options 0

9379 SPRINTER, 2022 110risk of bias not avaialble